Moderna

Nikos Pekiaridis | Nurphoto | Getty ImagesModerna on Thursday posted a surprise quarterly profit, in part boosted by deferred revenue, even as the company saw slumping sales from its Covid vaccine, its only marketable product. The results cap a rocky year for the biotech company and other Covid vaccine makers, which all saw revenue plunge as the world continued to emerge from pandemic and relied less on protective shots and treatments.Here's what Moderna reported for the fourth quarter compared with what Wall Street was…

Nikos Pekiaridis | Lightrocket | Getty ImagesModerna on Monday said its Covid vaccine sales plunged by about two-thirds in 2023 to $6.7 billion, as fewer people rolled up their sleeves for an updated version of the jab.The revenue from the shots met Moderna's forecast for the year, even as sales plummeted from the more than $18 billion the company booked in 2022. Moderna's announcement, which came ahead of its presentation at the annual JPMorgan Healthcare Conference, shows the steep drop in demand for Covid products last…

You might think a biotech company that created a new vaccine, using novel tech like mRNA-based therapeutics, in record time to help the world fight a historic pandemic like COVID-19 would still be flying high. That hasn’t been the case so far for Moderna, whose only FDA-approved product to date remains its COVID vaccine Spikevax and its various forms for teens and children. But a new analyst report from Oppenheimer released this week asserts the company’s pipeline of mRNA-based vaccine candidates, for infectious diseases…

Artur Widak | Nurphoto | Getty ImagesShares of Moderna jumped more than 15% on Tuesday after Oppenheimer upgraded the stock to "outperform," saying the Covid vaccine maker could market five products by 2026.The upgrade follows a dismal 2023 for Moderna, whose only commercially available product is its Covid shot. The company's stock has long been tied to its vaccine, and its shares fell nearly 40% last year as demand for Covid products plummeted worldwide. Oppenheimer analyst Hartaj Singh said the company's Covid sales…

An exterior view of Moderna's clinical manufacturing facility. David L. Ryan | Boston Globe | Getty ImagesModerna and Merck's experimental cancer vaccine, when used in combination with Merck's blockbuster therapy Keytruda, reduced the risk of death or relapse in patients with the most deadly form of skin cancer after three years, according to midstage trial data released Thursday. The combination specifically slashed the risk of death or recurrence of the cancer, known as melanoma, by 49% in patients in later stages of…

China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere. China remains attractive to global pharmaceutical companies even as many multinationals shift their focus elsewhere. FOLLOW US ON GOOGLE NEWS Read original article here Denial of responsibility! Techno Blender is an automatic aggregator of the all world’s media. In each content, the hyperlink to the primary source is specified. All trademarks belong to their rightful owners, all materials to…

Nikos Pekiaridis | Nurphoto | Getty ImagesModerna on Wednesday said it struck a deal with Chinese officials to research, develop and manufacture messenger RNA medicines in the country, despite rising tensions between the U.S. and China. The Massachusetts-based biotech company signed a memorandum of understanding and a related land collaboration deal to develop drugs that will "be exclusively for the Chinese people" and "not be exported," a Moderna spokesperson told CNBC.  Chinese media outlet Yicai first reported on…

Vaccines for a common but sometimes dangerous virus are well on the way to reaching the public. This month, outside experts assembled by the Centers for Disease Control and Prevention gave their blessing to two vaccines developed against the respiratory syncytial virus, or RSV. The vaccines, approved for older adults, are expected to be available in the U.S. by this fall.Is Google's New $1,800 Pixel Phone Worth It? | Gizmodo ReviewRSV often causes little more than a common cold. But the infection can occasionally reach…

A vial and a medical syringe seen displayed in front of the Food and Drug Administration (FDA) of the United States and Moderna biotechnology company's logos. FDA finds the COVID-19 vaccine.Pavlo Gonchar | LightRocket | Getty ImagesModerna on Thursday applied for U.S. Food and Drug Administration approval of the biotech company's updated Covid vaccine for the fall. The shot targets omicron subvariant XBB.1.5, the dominant strain of the virus nationwide. Moderna said the submission is based on the FDA's recommendation last…

A pharmacist prepares to administer COVID-19 vaccine booster shots during an event hosted by the Chicago Department of Public Health at the Southwest Senior Center on September 09, 2022 in Chicago, Illinois.Scott Olson | Getty ImagesThe U.S. Food and Drug Administration's Covid strain selection for the next round of shots puts Pfizer, Moderna and Novavax on track to deliver new jabs in time for the fall – a decisive win for the vaccine makers as they gear up to compete against one another.  The FDA on Friday advised the…